Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 7/20 | 0.46 |
| ▸ | CES1 | P23141 | 6/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819098 | 0.88 | AKT1 (0.52) | HDAC1HDAC3HDAC2NCOR2AKT1 | |
| SCHEMBL13256485 | 0.81 | HDAC3 (0.38) | HDAC1HDAC3HDAC2NCOR2AKT1 | |
| SCHEMBL12410847 | 0.81 | LOXL2 (0.50) | HDAC1HDAC3HDAC2NCOR2RAB9A | |
| SCHEMBL20341352 | 0.80 | AKT1 (0.49) | HDAC1HDAC3HDAC2NCOR2AKT1 | |
| SCHEMBL6792190 | 0.79 | GRM2 (0.43) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL3713674 | 0.79 | CES2 (0.60) | HDAC1HDAC3CES2CES1RAB9A | |
| SCHEMBL8360300 | 0.79 | HDAC3 (0.43) | HDAC1HDAC3HDAC2NCOR2AKT1 | |
| SCHEMBL19153416 | 0.78 | AKT1 (0.43) | HDAC1HDAC3HDAC2NCOR2CES2 | |
| SCHEMBL7944783 | 0.78 | GRM2 (0.44) | HDAC1HDAC3HDAC2NCOR2AKT1 | |
| SCHEMBL357503 | 0.78 | AKT1 (0.47) | HDAC1HDAC3HDAC2NCOR2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | HDAC1 329/4885HDAC3 561/4885HDAC2 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.